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1. Introduction 
Derangement of hormonal milieu has been associated with the pathophysiology of 
psychiatric illnesses, such as schizophrenia, mood disorders, and developmental disorders 
[1; 2; 3]. Among them, schizophrenia is a relatively common neuropsychiatric disorder, and 
has been associated with debilitating consequences if not treated properly [4; 5]. The illness 
is characterized by positive (e.g., delusions, hallucinations, bizarre thoughts) and negative 
(blunt affect, avolition, anhedonia, social withdrawal) symptoms, as well as deficits in 
various cognitive abilities, e.g. verbal memory, working memory, attention/vigilance, and 
information processing [4; 6; 7]. Minor impairments of social cognition are often observed 
during the premorbid stage of the disease [8]. 
The role for endocrinological dysregulation in the development of psychotic symptoms has 
been suggested by brain imaging studies. For example, a larger than normal volume of the 
pituitary gland has been reported in patients with first-episode schizophrenia [9] (Fig. 1). 
Further, these patients exhibit an increase in the pituitary volume overtime, unlike the case 
with normal volunteers, the degree of which is correlated with the change in positive 
symptoms [9]. These findings, representing mainly a morphological change of the anterior 
pituitary [9], are consistent with the concept of HPA axis hyperactivity in response to stress 
during psychotic experience [10].  
Hormones secreted from the posterior portion of the pituitary gland, i.e. vasopressin and 
oxytocin, have also been a focus in schizophrenia research from the perspective of social 
behavior disturbances [2; 11; 12]. In this chapter, we provide an overview of preclinical and 
clinical evidence for contribution of the vasopressin and oxytocin systems in social behavior 
deficits of schizophrenia and related disorders, as well as their treatment. Related 
discussions on the role of these neuropeptides in the coping of stressors and psychiatric 
conditions are provided in other Chapters [3; 13].  
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Figure 1. Sagittal (A) and coronal (B) views of the pituitary gland manually traced (in blue). The 
pituitary stalk was excluded from the tracings. (Takahashi T et al. Prog Neuropsychopharmacol Biol 
Psychiatry 35;177-83, 2011 (Permission obtained from Elsevier)  
2. Vasopressin (arginine-vasopressin, AVP), oxytocin and behaviors  
The two neuro-hormones are nona-peptides closely related each other, while their functions 
are sometimes in opposite directions, e.g. facial cognition and responses to stress [14]. Also, 
there is a suggestion that oxytocin is responsible for maternal behavior whereas male-typical 
social behavior is associated with AVP [2]. As a neuromodulator, AVP has been suggested 
to play a role in some of the cognitive abilities, including social memory, as well as 
emotionality (Fig 2). Neurotransmissions by AVP are mediated by three receptor subtypes, 
namely, V1A, V1B, and V2 receptors, all of which are coupled to G-proteins [2]. Information 
about oxytocin is reviewed elsewhere in this Book [3] 
Impaired social abilities have been particularly implicated in subjects with developmental 
disorders, such as autism. Thus, Fries et al (2005) [15] reported decreased urine levels of 
AVP and oxytocin, in children reared in orphanage settings compared to those in infants 
who received normal care-giving from their parents. Previously institutionalized children 
have been suggested to frequently experience problems in establishing social bonds and 
regulating social behavior [15]. Accordingly, infants who experienced early neglect showed 
lower basal levels of AVP than family-reared children [15]. These observations support the 
growing evidence for the role of the neuropeptidergic systems in social behaviors in 
mammals (e.g. [16; 17; 18]: see [19] for review).  
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Figure 2. Arginine-vasopressin in the brain and periphery. Extracted from Frank E and Landgraf R. Eur 
J Psychopharmacol 583;226-42, 2008 (Permission obtained from Elsevier)  
3. Sociality deficits in animal models of schizophrenia; Effect of 
neuropeptides 
Social behaviors comprise various domains, such as social (learning) memory and social 
bonding [20; 21]. The intracerebroventricular administration of AVP has been shown to 
facilitate social memory, as measured by the social discrimination test (SDT), in rats [22; 23].  
The neural substrates governing the ability of AVP to enhance sociality include the lateral 
septum (LS), bed nucleus of the stria terminalis, and medial amygdala [24]. Specifically, 
overexpression of the V1A receptors in the LS enhanced SDT performance, an effect blocked  
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Figure 3. Autoradiographic localization of V1a receptor binding sites in coronal sections of the brain of the 
vehicle group (A–D) and PCP group (E–H) of rats with [125I]-Linear AVP antagonist. Abbreviations: Acb, 
nucleus accumbens; FStr, fundus striati; LS, lateral septum; BST, bed nucleus of the stria terminalis; Ce, 
central amygdaloid nucleus; DG, dentate gyrus; VM, ventromedial thalamic nucleus; LH, lateral 
hypothalamic area; Rli, rostral linear raphe nucleus; SN, substantia nigra; IP, interpeduncular nucleus; SC, 
superior colliculus. Tanaka et al ., Brain Res 992; 239–245, 2003 (Permission obtained from Elsevier)  
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by application of a V1A antagonist, but not oxytocin receptor antagonist [2]. By contrast, 
administration of oxytocin into the medial amygdala restored impaired social recognition in 
oxytocin knockout mice, while vasopressin was ineffective [25]. Overall, these observations 
are consistent with the contribution of V1 receptors in the LS to the maintenance of long-
term potentiation [26], which is crucial for learning and memory.  
Experimental data from our laboratory also suggest a role for altered AVP transmissions in 
social interaction deficits. Thus, chronic administration of phencyclidine, an antagonist at N-
methyl-D-aspartate (NMDA) receptors, impaired social interaction behavior, and reduced 
the density of V1A receptors in several brain regions, including the LS in rats [18] (Figure 3). 
In a subsequent study, Matsuoka et al. (2008) [27] found decreased levels of mRNA 
encoding AVP in the amygdala, as measured by a microarray system and real-time 
quantitative PCR assay, in rats chronically treated with MK-801, a non-competitive 
antagonist at the NMDA receptor. These findings provide a basis for the ability of AVP or 
its analogues to ameliorate social interaction deficits in animal models of schizophrenia.  
Accordingly, we reported that NC-1900, an AVP analogue and agonist at V1a receptors, 
ameliorates social interaction deficits in rats chronically treated with MK-801 [17] (Figure 4).  
 
Figure 4. Measurement of social interaction behavior. A pair of rats (one dye-marked) are placed in an 
open arena, whose behavior, including “contact” (between-subject distance < 20 cm) is video-taped for 
manual viewing and/or automatically analyzed by a computer. (Inset )Total duration of contact (TDC) 
of rats during a 10-min observation period. Each bar represents mean ± SD of the time spent in social 
interaction (in seconds). *P < 0.05, chronic (MK-801, vehicle) × acute (NC-1900, vehicle) treatment 
interaction.  Matsuoka et al. Brain Res 1053 (2005) 131-136. (Permission obtained from Elsevier). 
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This result from an animal model of schizophrenia is consistent with the observation, 
discussed above [18], that chronic administration of the NMDA antagonist phencyclidine 
reduces the density of V1a receptor binding sites in several brain regions, including the LS, 
in rats showing social interaction deficits. These findings from our laboratory are consistent 
with Bielsky et al [16] who reported that re-expressing of V1a receptors in the lateral septum 
of V1a receptor knockout mice exhibits complete recovery from impaired social recognition. 
Down-regulation of the AVP gene in the amygdala of MK-801-treated rats may provide a 
basis for the ability of AVP-analogues to ameliorate the behavioral disturbances by blockade 
of NMDA receptor [17]. Similar benefits regarding social behavior have been reported for 
oxytocin [3; 13; 28; 29; 30]. 
We conducted a further analysis of the change in the expression of RNAs encoding AVP and 
its receptor subtypes (V1A, V1B) in the amygdala of the model rat by means of qPCR (Table 1). 
As shown in Fig 5, expression of the AVP gene was significantly reduced by treatment with 
MK-801 (0.13 mg/day) for 14 days, while the same treatment did not affect the expressions 
of V1A, and V1B receptors. These results may help understand a mechanism by which 
impaired NMDA receptor-mediated transmissions, a putative pathophysiology of 
schizophrenia, disturbs social behaviors. 
 
Figure 5. RNA quantification by means of real-time qPCR. Expression ratios for MK-801-treated rats vs. 
vehicle-treated animals are shown (n=5-6 for each group). Expression of the arginine-vasopressin (AVP) 
gene was significantly reduced by treatment with MK-801 (0.13 mg/day) for 14 days, (*p<0.05 by one-way 
ANOVA), while the same treatment did not affect the expressions of V1a and V1b receptors.Mx3000P 
(StrataGene) was used for pPCR with SYBER Premix Ex Taq (Takara Co. Ltd.). GAPDH was used as 
internal standard. 
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Table 1. Nucleotide sequences of RT-qPCR primers for target genes 
4. Clinical implications 
Efforts to enhance social ability are important from the perspective of adjusting patients to the 
community, thus improving functional outcome. Social ability disturbances in schizophrenia 
are thought to be partly attributable to negative symptoms and disturbances of cognitive 
function [4; 31; 32]. Although treatment with the first generation antipsychotic drugs, e.g. 
haloperidol, has been shown to ameliorate positive symptoms, only a limited number of 
agents, such as the second generation antipsychotics, or so-called “atypical antipsychotic drugs 
(AAPDs)”, e.g. clozapine, melperone, risperidone, olanzapine, quetiapine, ziprasidone, and 
perospirone, with variable affinities for serotonin (5-HT) receptor subtypes, have been shown 
to be partially effective to treat negative symptoms and cognitive disturbances of 
schizophrenia [32; 33; 34; 35; 36] (see [4; 37] for review). Thus, more effective strategy to treat 
neurocognition, in addition to social abilities, is needed to enhance quality of life for patients. 
In this context, the results from a recent study of the effect of augmentation therapy with 
oxytocin on cognitive function in patients with schizophrenia are noteworthy [38]. The 
investigators report a significant enhancement of verbal learning memory, a cognitive 
domain thought to largely influence the outcome, in subjects receiving daily intranasal 
oxytocin (twice daily) for 3 weeks. Further controlled study is warranted to confirm the 
cognition-boosting effect of neuropeptides in the treatment of schizophrenia. 
As has been discussed, neuropeptides, e.g., vasopressin and oxytocin, have been suggested 
to be associated with the pathophysiology of schizophrenia. Accordingly, a whole-genome 
scan for schizophrenia in a large inbred Arab-Israeli pedigree has found a possible linkage 
on chromosome 20p13 [39] (Fig. 6). Importantly, this locus harbors four strong candidate 
genes for the illness, two of which are for oxytocin (OXT) and AVP (AVP) [39]. Further, 
examination of the association with gene expression in the brain identified genetic variants 
in the OXT-AVP cluster, and three of these variants were associated with schizophrenia [12]. 
These findings provide a strong proof for the contribution of these neuropeptides to the 
etiology of the illness.  
 
Figure 6. A scheme of the genes oxytocin and vasopressin on the chromosomal region 20p13 and the 
positions of the seven examined SNPs. Teltsh et al., Int J Neuropsychopharmacol 15;309-19, 2012 
(Permission obtained from CINP). 
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5. Conclusions 
Psychotropic drugs acting on 5-HT receptors, such as AAPDs and 5-HT1A agonists, have 
been shown to improve social behavior in animals [36; 40; 41]. These results are consistent 
with the concept that the AVP and 5-HT systems interact both neuroanatomically and 
neurochemically in the brain areas, e.g. anterior hypothalamus, as demonstrated in Fig. 7 
[42]. Therefore, it is reasonable that further research into the neuropeptidergic system, in 
conjunction with other neurotransmitter/modulator systems, will facilitate the therapeutic 
strategy for social behavior deficits in patients with schizophrenia and related disorders. 
 
Figure 7. Photomicrographs of arginine vasopressin (AVP) and serotonin (5-HT), as revealed by 
double-labelling immunocytochemistry. Shown are AVP and 5-HT fluorescent immunoreactivity 
acquired through laser scanning confocal microscopy. The same single optical plane is shown for both 
neurochemical signals in the top black and white photographs. The combination of both digitized 
images is shown in color on the top right panel. The AVP is depicted in bright yellow and the 5-HT 
appears as a red/orange. A volume-rendered data set of serial optical sections through the AVP neuron 
denoted with the star is shown in the bottom color photograph. The green stippling is 5-HT varicosities 
and putative synapses clustered around the red-colored AVP neuron (denoted by the star). Scale bars: 
top, 50 μm; bottom, 30 μm. (Ferris C F et al. J. Neurosci. 1997;17:4331-43) (Permission obtained from the 
Society for Neuroscience) 
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